

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete If Known

INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

(use as many sheets as necessary)

RECEIVED

AUG 21 2001

Sheet **TECH CENTER 1600/2900**

4

Application Number **09/589,287**
Filing Date **June 8, 2000**
First Named Inventor **YU et al.,**
Group Art Unit **1646**
Examiner Name **Prasad, S.**
Attorney Docket Number **PF343P3C1**

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. ¹ | U.S. Patent Document Number | Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-------------------|-----------------------|-----------------------------|-----------------------------------|---|--|---|
| SEP | A1 | 08/984,396 | | SmithKline Beecham | NA | Priority Document of EP 869180 |
| | A2 | 60/033,601 | | Schering | NA | Priority Document of WO 98/27114 |
| | A3 | 60/041,797 | | SmithKline Beecham | NA | Priority Document of EP 869180 |
| | A4 | 60/048,776 | | Regeneron | NA | Priority Document of 98/55620 & 98/55621 |
| | A5 | 60/058,786 | | Biogen | NA | Priority Document of 99/12964 |
| | A6 | 60/066,386 | | Regeneron | NA | Priority Document of 98/55620 & 98/55621 |
| | A7 | 60/066,577 | | Eli Lilly | NA | Priority Document of EP 921194 |
| | A8 | 60/068,959 | | Chiron | NA | Priority Document of WO 99/33980 |
| | A9 | 60/096,173 | | Eli Lilly | NA | Priority Document of EP 921194 |
| | A10 | 60/106,976 | | U.S. Government - DHHS | NA | Priority Document of WO 00/26244 |
| | A11 | 60/117,169 | | Biogen | NA | Priority Document of WO 00/43032 |
| | A12 | 60/143,228 | | Biogen | NA | Priority Document of WO 00/43032 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| SEP | A13 | EP | 869180 | A1 | SmithKline Beecham | 07-10-1998 | | |
| | A14 | EP | 921194 | A2 | Eli Lilly | 06-09-1999 | | |
| | A15 | EP | 98302526 | | SmithKline Beecham | 4/98 | Priority Document of EP 869180 | |
| | A16 | EP | 98309632 | | Eli Lilly | 11/98 | Priority Document of EP 921194 | |
| | A17 | WO | 01/40466 | A2 | Genentech | 06-07-2001 | Pages 1-135 and Figures 23 and 24 | |
| | A18 | WO | 00/26244 | A2 | U.S. Government - DHHS | 05-11-2000 | | |
| | A19 | WO | 00/39295 | A1 | Glaxo | 07-06-2000 | | |
| | A20 | WO | 00/40716 | A2 | Zymogenetics | 07-13-2000 | | |
| | A21 | WO | 00/43032 | A2 | Biogen | 07-27-2000 | | |
| | A22 | WO | 00/47740 | A2 | Amgen, Inc. | 08-17-2000 | | |
| | A23 | WO | 00/45836 | A1 | Res. Dev. Foundation | 08-10-2000 | | |
| | A24 | WO | 00/60079 | A2 | Chiron Corporation | 10-12-2000 | | |
| | A25 | WO | 00/67034 | A1 | Immunex Corporation | 11-09-2000 | | |

Sarada Prasad

09/31/01

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | | | |
|--|---|----|---|-------------------|--|
| Substitute for form 1449A/PTO | | | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary) | | | | | |
| Application Number | | | | 09/589,287 | |
| Filing Date | | | | June 8, 2000 | |
| First Named Inventor | | | | YU et al., | |
| Group Art Unit | | | | 1646 | |
| Examiner Name | | | | Prasad, S. | |
| Attorney Docket Number | | | | PF343P3C1 | |
| Sheet | 2 | of | 4 | | |



| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| Examiner Initials | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| SCP | A26 | WO | 00/68378 | A1 | National Jewish Medical and Research Center | 11-16-2000 | | |
| ↓ | A27 | WO | 00/77256 | A1 | Human Genome Sciences | 12-21-2000 | | |
| | A28 | WO | 97/33902 | A1 | Human Genome Sciences | 09-18-1997 | | |
| | A29 | WO | 98/27114 | A2 | Schering | 06-25-1998 | | |
| | A30 | WO | 98/55620 | A1 | Regeneron | 12-10-1998 | | |
| | A31 | WO | 98/55621 | A1 | Regeneron | 12-10-1998 | | |
| | A32 | WO | 99/11791 | A1 | Univ. of Washington | 03-11-1999 | | |
| | A33 | WO | 99/12964 | A2 | Biogen | 03-18-1999 | | |
| ↓ | A34 | WO | 99/33980 | A2 | Chiron | 07-08-1999 | | |

| OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS | | | | |
|--|-----------------------|---|----------------|--|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ | |
| SCP ↓ | A35 | FARRAH ET AL., GenBank Accession Number AF186114, 01-13-2000. | | |
| | A36 | FERGUSON ET AL., Human Molecular Genetics 6:1589-1594 | | |
| | A37 | FUJIWARA ET AL., GenBank Accession Number D79690, 02-09-1996. | | |
| | A38 | HILLIER ET AL., GenBank Accession Number AA166695, 11-09-1997. | | |
| | A39 | HILLIER ET AL., GenBank Accession Number AA682496, 12-19-1997. | | |
| | A40 | HILLIER ET AL., GenBank Accession Number R16882, 04-14-1995. | | |
| | A41 | HILLIER ET AL., GenBank Accession Number R16934, 04-14-1995. | | |
| | A42 | HILLIER ET AL., GenBank Accession Number T87299, 03-17-1995. | | |
| | A43 | MARRA ET AL., GenBank Accession Number AA422749, 10-16-1997. | | |
| | A44 | MARRA ET AL., GenBank Accession Number AI182472, 10-08-1998. | | |
| | A45 | MYERS., GenBank Accession Number G30081, 10-05-1996. | | |
| | A46 | NCI-CGAP., GenBank Accession Number AA906714, 06-09-1998. | | |
| | A47 | ZHANG ET AL., GenBank Accession Number AF134715, 03-28-2000. | | |

RECEIVED

AUG 21 2001

TECH CENTER 1600/2900

Sayada Prasad

14/31/01

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.


Please type a plus sign (+) inside this box ?



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|--|------------------------|--------------|
| Substitute for form 1449A/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary) | | | |
| | | Application Number | 09/589,287 |
| | | Filing Date | June 8, 2000 |
| | | First Named Inventor | YU et al., |
| | | Group Art Unit | 1646 |
| | | Examiner Name | Prasad, S. |
| Sheet 3 of 4 | | Attorney Docket Number | PF343P3C1 |



| OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS | | | |
|--|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| Scp | A48 | BAUMGARTH, Nicole, Secreted IgM versus BlyS in germinal center formation, Nature Immunology, (2000) 1:179. | |
| | A49 | CYSTER, JASON G., Marginal zone B cells may steal the limelight as the roles of Pyk-2 and BlyS begin to be elucidated. Pyk-2 deficiency leads to their loss whereas signaling via the BlyS receptor may augment their function, Nature Immunology, (2000) 1:9-10. | |
| | A50 | DO ET AL., Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response, J. Exp. Med., (2000) 192:953-964. | |
| | A51 | GROSS ET AL., TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease, Nature, (2000) 404:995-999. | |
| | A52 | HATZOGLOU ET AL., TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase, The Journal of Immunology, (2000) 165:1322-1330. | |
| | A53 | HU ET AL., Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily, Genomics, 62:1023-107 (1999). | |
| | A54 | KANAKARAJ ET AL., BlyS Binds to B Cells With High Affinity and Induces Activation of the Transcription Factors NF-κ and Elf-1, Cytokine (2001) 13:25-31. | |
| | A55 | KHARE ET AL., Severe B Cell Hyperplasia and autoimmune disease in TALL-1 transgenic mice, PNAS, (2000) 97:3370-3375. | |
| | A56 | LAABI ET AL., Lymphocyte Survival--Ignorance is BlyS, Science Magazine, (2001) 289:883. | |
| | A57 | MACKAY ET AL., Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations, J. Exp. Med., (1999) 190:1697-1710. | |
| | A58 | MARSTERS, ET AL., Interaction of the TNF homologues BlyS and APRIL with the TNF receptor homologues BCMA and TACI, Current Biology, (2000) 10:785-788. | |
| | A59 | MOORE ET AL., BlyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator, Science, (1999) 285:260-263. | |
| | A60 | NARDELLI ET AL., Synthesis and release of B-lymphocyte stimulator from myeloid cells, Immunobiology, (2001) 97:198-204. | |
| | A61 | PARRY ET AL., Pharmacokinetics and Immunological Effects of Exogenously administered Recombinant Human B Lymphocyte Stimulator (BlyS) in Mice, The Journal of Pharmacology and Experimental Therapies, (2001) 296:396-404. | |
| | A62 | SCHNEIDER ET AL., BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, J. Exp. Med., (1999) 189:1747-1756. | |
| | A63 | SHU ET AL., TALL-1 is a novel member of the TNF Family that is Down-regulated by Mitogens, J. Leukoc. Biol., 65:680-683 (1999). | |

RECEIVED

AUG 21 2001

TECH CENTER 1600/2900

Sarada Prasad

10/31/01

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|--|---|------------------------|--------------|
| Substitute for form 1449A/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary) | | | |
| | | Application Number | 09/589,287 |
| | | Filing Date | June 8, 2000 |
| | | First Named Inventor | YU et al., |
| | | Group Art Unit | 1646 |
| | | Examiner Name | Prasad, S. |
| Sheet | 4 | of | 4 |
| | | Attorney Docket Number | PF343P3C1 |

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-------------------|-----------------------|---|----------------|
| SCP | A64 | THOMPSON ET AL., BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population, J. Exp. Med., (2000) 192:129-135. | |
| | A65 | WU ET AL., Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI Is a High Affinity Receptor for TNF Family Members APRIL and BlyS, The Journal of Biological Chemistry (2000) 275:34578-34585. | |
| | A66 | XIA ET AL., TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation, J. Exp. Med., (2000) 192:137-143. | |
| | A67 | YAN ET AL., Identification of a receptor for BlyS demonstrates a crucial role in humoral immunity, Nature Immunology, (2000) 1:37-41. | |
| | A68 | YU ET AL., APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity, (2000) 1:252-256. | |
| | A69 | ZHANG ET AL., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus, The Journal of Immunology, (2001) 166:6-10. | |
| | | | |
| | | | |

| | | | |
|----------|---------------|-----------------|----------|
| Examiner | Sarada Prasad | Date Considered | 10/31/01 |
|----------|---------------|-----------------|----------|

RECEIVED

AUG 21 2001

TECH CENTER 1600/2900

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.